ImmuCell 2025 Sales Up 4.3% to $27.6M with $1.6M Operating Income
ImmuCell reported 2025 product sales rose 4.3% to $27.6 million, boosting gross profit margin to 41.4% from 30% and generating net operating income of $1.6 million, up $3.3 million year-over-year. Net loss narrowed to $1.0 million from $2.2 million despite $2.7 million Re-Tain® asset write-downs and $651,000 colostrum inventory charges.
1. 2025 Financial Results
ImmuCell’s unaudited results for the year ended December 31, 2025 show product sales climbed 4.3% to $27.6 million, gross profit margin expanded to 41.4% from 30%, and net operating income reached $1.6 million compared to a loss of $1.6 million in 2024.
2. Net Loss and Non-Recurring Charges
The company recorded a net loss of $1.0 million, or ($0.12) per share, an improvement of $1.1 million versus 2024. Non-recurring charges included a $2.7 million write-down of Re-Tain® assets, $651,000 in colostrum inventory write-downs and $297,000 of CEO transition costs, partially offset by $427,000 of insurance proceeds.
3. Operational Highlights and Outlook
Average monthly output rose to 380,000 units in 2025 from 345,000 in 2024, driven by manufacturing efficiencies and price realization. Cash and cash equivalents held at $3.8 million, net working capital increased to $13.0 million, and the company plans to prioritize its First Defense® franchise and further commercial expansion.